• Citer

The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology

par Rozenberg, Serge ;Praet, Julie;Pazzaglia, Elisa ;Gilles, Christine ;Manigart, Yannick ;Vandromme, Jean
Référence Australian and New Zealand Journal of Obstetrics and Gynaecology, 57, 4, page (393-399)
Publication Publié, 2017-08

Article révisé par les pairs

• Détails
• Contenu

Résumé :

This review discusses the development of selective progestin receptor modulators (SPRMs) for use in women's health and specifically the use of ulipristal acetate (UPA) as emergency contraception (EC) and as a treatment for symptomatic fibroids in women who want to preserve their fertility or avoid a hysterectomy. As an EC, UPA 30 mg should be recommended for women, within 102 h of unprotected intercourse. As a treatment of fibroids, UPA (5 mg daily dose) should be administered for periods of three months as a pre-surgical strategy, reducing bleeding and fibroid size and facilitating surgery. A proportion of these patients may even avoid surgery. Future developments will demonstrate whether UPA can be used for other indications such as endometriosis and breast cancer prevention or treatment.